(Q44961465)

English

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension (English)

1 reference

Europe PubMed Central

7 December 2017

1 reference

based on heuristic

inferred from title

Kristine Ensrud

1

object named as

Kristine E Ensrud

1 reference

Europe PubMed Central

7 December 2017

12

object named as

Dennis M Black

1 reference

Europe PubMed Central

7 December 2017

3

object named as

Ann Schwartz

1 reference

Europe PubMed Central

7 December 2017

Douglas C Bauer

5

object named as

Douglas C Bauer

1 reference

Europe PubMed Central

7 December 2017

Arthur C. Santora

4

object named as

Arthur C Santora

1 reference

Europe PubMed Central

7 December 2017

Marc C. Hochberg

9

object named as

Marc C Hochberg

1 reference

Europe PubMed Central

7 December 2017

Elizabeth Barrett-Connor

2

object named as

Elizabeth L Barrett-Connor

1 reference

Europe PubMed Central

7 December 2017

Adrianne C Feldstein

7

object named as

Adrianne Feldstein

1 reference

Europe PubMed Central

7 December 2017

William Haskell

8

object named as

William L Haskell

1 reference

Europe PubMed Central

7 December 2017

author name string

Shailaja Suryawanshi

6

1 reference

Europe PubMed Central

7 December 2017

James C Torner

10

1 reference

Europe PubMed Central

7 December 2017

Antonio Lombardi

11

1 reference

Europe PubMed Central

7 December 2017

Fracture Intervention Trial Long-Term Extension Research Group

13

1 reference

Europe PubMed Central

7 December 2017

publication date

29 March 2004

1 reference

Europe PubMed Central

7 December 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

7 December 2017

19

1 reference

Europe PubMed Central

7 December 2017

1259-1269

1 reference

Europe PubMed Central

7 December 2017

8

1 reference

Europe PubMed Central

7 December 2017

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Design of the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone microdamage and skeletal fragility in osteoporotic and stress fractures

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Timing of estrogen replacement therapy for optimal osteoporosis prevention.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Osteoporosis and fractures in postmenopausal women using estrogen.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Acid peptic disease in the elderly

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Bone matters: are density increases necessary to reduce fracture risk?

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.040326

21 January 2018

Identifiers

10.1359/JBMR.040326

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44961465&oldid=2083588474"